Publication: Real-life effect of a microcrystalline tyrosine adjuvanted mite immunotherapy in patients with allergic rhinitis.
No Thumbnail Available
Identifiers
Date
2020-01-08
Authors
Roger, Albert
Malet, Alfons
Moreno, Victoria
Parra, Antonio
Gutiérrez, Diego
Lleonart, Ramón
Moreno, Francisco
Valero, Antonio
Navarro, Begoña
Hinojosa, Belén
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
Aim: Evaluate the effectiveness and safety of immunotherapy with Acarovac Plus® in a 1-year prospective multicentered real-life study. Methods: A total of 118 adults with allergic rhinitis sensitized to Dermatophagoides received subcutaneous immunotherapy with Acarovac Plus. Treatment outcomes were evaluated at baseline, 6 months and 1 year after treatment initiation. Primary end point was the evolution of the combined symptom and medication score. Secondary end points included other effectiveness outcomes and measurement of product tolerability. Results: Acarovac Plus induced significant improvements in primary and secondary end points after 6 months compared with baseline. These differences persisted after 1 year of treatment (p
Description
MeSH Terms
Adjuvants, Immunologic
Adolescent
Adult
Aged
Animals
Antigens, Dermatophagoides
Desensitization, Immunologic
Female
Humans
Injections, Subcutaneous
Male
Middle Aged
Novobiocin
Prospective Studies
Pyroglyphidae
Rhinitis, Allergic
Treatment Outcome
Tyrosine
Young Adult
Adolescent
Adult
Aged
Animals
Antigens, Dermatophagoides
Desensitization, Immunologic
Female
Humans
Injections, Subcutaneous
Male
Middle Aged
Novobiocin
Prospective Studies
Pyroglyphidae
Rhinitis, Allergic
Treatment Outcome
Tyrosine
Young Adult
DeCS Terms
CIE Terms
Keywords
Dermatophagoides pteronyssinus, adjuvants, allergic rhinitis, effectiveness, house dust mites, real-life clinical practice, safety, subcutaneous allergen immunotherapy